Aurobindo Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) inspected Unit-IV of APL Healthcare, a wholly owned subsidiary of the Company, situated at Palchur village and part of Palepalem Village Naidupeta Mandal, SPSR Nellore District, 524126, Andhra Pradesh, from 08 December to 17 December 2025.

At the end of the current inspection, a 'Form 483' was issued with 05 observations which are procedural in nature, and we will respond to the US FDA within the stipulated timelines.

Powered by Capital Market - Live News

The inspection was conducted from 8 December to 17 December 2025. At the end of the current inspection, a ?Form 483? was issued with 5 observations which are procedural in nature, and the company said that it will respond to the US FDA within the stipulated timelines.

Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services.

The company?s consolidated net profit increased 3.8% to Rs 848.45 crore on 7.7% increase in net sales to Rs 8,236.96 crore in Q2 FY26 over Q2 FY25.

The scrip rose 0.36% to Rs 1,197.40 on the BSE.

Powered by Capital Market - Live News

Aurobindo Pharma Ltd is up for a fifth straight session today. The stock is quoting at Rs 1218.8, up 0.71% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.26% on the day, quoting at 25811.05. The Sensex is at 84221.24, down 0.3%. Aurobindo Pharma Ltd has gained around 9.9% in last one month.

Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has gained around 3.23% in last one month and is currently quoting at 22686.8, up 0.36% on the day. The volume in the stock stood at 10.7 lakh shares today, compared to the daily average of 13.98 lakh shares in last one month.

The benchmark November futures contract for the stock is quoting at Rs 1223.1, up 0.95% on the day. Aurobindo Pharma Ltd is down 1.34% in last one year as compared to a 10.05% jump in NIFTY and a 5.69% jump in the Nifty Pharma index.

The PE of the stock is 35.05 based on TTM earnings ending September 25.

Powered by Capital Market - Live News

Aurobindo Pharma has received the Establishment Inspection Report (EIR) issued by the USFDA classifying Unit 1 of Apitoria Pharma, a wholly owned subsidiary of the company as 'Voluntary Action Indicated (VAI)'.

Powered by Capital Market - Live News